Krsnaa Diagnostics Ltd (KRSNAA) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Krsnaa Diagnostics demonstrated strong performance in Q1 FY26, driven by growth in both radiology and pathology segments.
- Revenue reached 1930 million, a 13% YoY increase.
- EBITDA grew by 19% YoY to 524 million, with a margin of 27%.
- Retail momentum accelerated, with touchpoints increasing from 362 to 2414 YoY, contributing 6% to overall revenue.
- The company won a transformative PPP award in Rajasthan, expanding its reach significantly.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.